Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precipio Inc PRPO

Healthcare
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through... see more

Recent & Breaking News (NDAQ:PRPO)

Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

GlobeNewswire March 21, 2022

Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022

GlobeNewswire February 24, 2022

New York State Approves Precipio's HemeScreen for POL clinical use

GlobeNewswire November 18, 2021

89bio Announces Appointment of Kathy LaPorte to its Board of Directors

GlobeNewswire November 3, 2021

Precipio Announces Q3-2021 and year-end Shareholder Update Call

GlobeNewswire November 1, 2021

American Oncology Network Partners with Precipio to Bring HemeScreen® into AON's Laboratory

GlobeNewswire August 26, 2021

Precipio Reschedules Q2-2021 Shareholder Update Call

GlobeNewswire August 20, 2021

Precipio Corrects Announcement of Q2-2021 Shareholder Update Call

GlobeNewswire August 13, 2021

Precipio Announces Q2-2021 and year-end Shareholder Update Call

GlobeNewswire August 12, 2021

Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M

GlobeNewswire July 28, 2021

Precipio Terminates its Equity Line

GlobeNewswire June 15, 2021

Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool

GlobeNewswire June 8, 2021

Precipio Announces Q1-2021 and year-end Shareholder Update Call

GlobeNewswire May 14, 2021

Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time

GlobeNewswire May 10, 2021

Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform

GlobeNewswire May 3, 2021

Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio's HemeScreen POL Offering by Q4-2021

GlobeNewswire April 26, 2021

Precipio Enters Into an At-The -Market (ATM) Financing Arrangement

GlobeNewswire April 5, 2021

Precipio Announces 95% Annual Growth YoY and 180% Quarterly Growth YoY

GlobeNewswire March 30, 2021

Precipio Announces Q4-2020 and year-end Shareholder Update Call

GlobeNewswire March 18, 2021

Mr. Ron Andrews joins Precipio's Board of Directors

GlobeNewswire March 3, 2021